Precede Biosciences Presents ESMO 2026 Data Revealing Biology Associated with Response and Resistance to PSMA-Directed Radioligand Therapy in Advanced Prostate Cancer
· Financial Post
ESMO 2026 Presentation
Comprehensive Plasma Epigenomic Profiling in mCRPC Elucidates Lineage States Associated with 177Lu-PSMA-617 Response and Resistance (Poster #8727) Read More
Comprehensive Plasma Epigenomic Profiling in mCRPC Elucidates Lineage States Associated with 177Lu-PSMA-617 Response and Resistance (Poster #8727) Read More
Visit newssport.cv for more information.